Subgroup analyses in patients with an ECOG PS score at least 2 and tumor PD-L1 TPS of at least 50%, any tumor PD-L1 TPS treated with pembrolizumab in the first-line setting, and tumor PD-L1 TPS of at least 50% who were treated with pembrolizumab in the first-line setting showed results consistent with prior studies, with the major exception of shorter OS in our cohort compared with the Pembrolizumab in Patients With Non–Small Cell Lung Cancer of Performance Status 2 (PePS2) trial7,14,15,16,17 (eTable 3 in the Supplement). The gene discussed is CD274; the disease is neoplasm.